Quarterly report [Sections 13 or 15(d)]

Condensed Consolidated Statements of Cash Flows (Unaudited)

v3.26.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Operating Activities    
Net loss $ (4,478) $ (1,318)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 926 225
Share-based compensation and restricted stock vesting 262 293
Amortization of right-of-use asset 228 116
Amortization of debt discount 1,914
Changes in fair value of warrant liability and warrant modification expense (1,436) (104)
Loss on issuance of convertible note 422
Changes in operating assets and liabilities:    
Accounts receivable, net (405) 180
Inventory (166) (70)
Prepaid expenses and other assets (586) (240)
Accounts payable 824 65
Accounts payable – related party 9 (84)
Accrued expenses and other current liabilities 252 224
Partnership advance (248)
Operating lease liability (217) (95)
Deferred revenue (2) 1
Net Cash Used in Operating Activities (2,701) (807)
Investing Activities    
Capital expenditures (85) (20)
Investment in BioNx (License Agreement) (6,502)
Net Cash Used in Investing Activities (6,587) (20)
Financing Activities    
Proceeds from convertible notes payable, net 10,203
Payment of contingent consideration (178)
Principal payment on financing lease liability (36) (29)
Financing costs (182)
Principal payments of notes payable (49) (48)
Net Cash Provided by (Used in) Financing Activities 9,936 (255)
Net Increase (Decrease) in Cash * 648 (1,082)
Cash and restricted cash – Beginning of period 1,058 1,807
Cash and restricted cash  – End of period 1,706 725
Supplemental Disclosure of Cash Flows Information    
Interest 18
Taxes
Supplemental Non-cash Investing and Financing activities    
Issuance of convertible notes and other liabilities in conjunction with license agreement 8,800
Issuance of securities for the conversion of convertible notes payable and accrued interest 1,000
Issuance of warrants in conjunction with convertible notes payable 3,858
Debt issued at a discount 179
Derivative liabilities recognized as debt discounts 10,101
Initial recognition of ROU asset and operating lease liabilities $ 1,617